TY - JOUR A1 - Hertlein, Tobias A1 - Sturm, Volker A1 - Jakob, Peter A1 - Ohlsen, Knut T1 - \(^{19}\)F Magnetic Resonance Imaging of Perfluorocarbons for the Evaluation of Response to Antibiotic Therapy in a Staphylococcus aureus Infection Model JF - PLoS ONE N2 - Background The emergence of antibiotic resistant bacteria in recent decades has highlighted the importance of developing new drugs to treat infections. However, in addition to the design of new drugs, the development of accurate preclinical testing methods is essential. In vivo imaging technologies such as bioluminescence imaging (BLI) or magnetic resonance imaging (MRI) are promising approaches. In a previous study, we showed the effectiveness of \(^{19}\)F MRI using perfluorocarbon (PFC) emulsions for detecting the site of Staphylococcus aureus infection. In the present follow-up study, we investigated the use of this method for in vivo visualization of the effects of antibiotic therapy. Methods/Principal findings Mice were infected with S. aureus Xen29 and treated with 0.9% NaCl solution, vancomycin or linezolid. Mock treatment led to the highest bioluminescence values during infection followed by vancomycin treatment. Counting the number of colony-forming units (cfu) at 7 days post-infection (p.i.) showed the highest bacterial burden for the mock group and the lowest for the linezolid group. Administration of PFCs at day 2 p.i. led to the accumulation of \(^{19}\)F at the rim of the abscess in all mice (in the shape of a hollow sphere), and antibiotic treatment decreased the \(^{19}\)F signal intensity and volume. Linezolid showed the strongest effect. The BLI, cfu, and MRI results were comparable. Conclusions \(^{19}\)F-MRI with PFCs is an effective non-invasive method for assessing the effects of antibiotic therapy in vivo. This method does not depend on pathogen specific markers and can therefore be used to estimate the efficacy of antibacterial therapy against a broad range of clinically relevant pathogens, and to localize sites of infection. KW - staphylococcus aureus KW - abscesses KW - vancomycin KW - antibiotics KW - magnetic resonance imaging KW - emulsions KW - bioluminescence imaging KW - in vivo imaging Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130113 VL - 8 IS - 5 ER - TY - JOUR A1 - Schröder, Wiebke A1 - Bernhardt, Jörg A1 - Marincola, Gabriella A1 - Klein-Hitpass, Ludger A1 - Herbig, Alexander A1 - Krupp, Guido A1 - Nieselt, Kay A1 - Wolz, Christiane T1 - Altering gene expression by aminocoumarins: the role of DNA supercoiling in Staphylococcus aureus JF - BMC Genomics N2 - BACKGROUND: It has been shown previously that aminocoumarin antibiotics such as novobiocin lead to immediate downregulation of recA expression and thereby inhibit the SOS response, mutation frequency and recombination capacity in Staphylococcus aureus. Aminocoumarins function by inhibiting the ATPase activity of DNA gyrase subunit B with a severe impact on DNA supercoiling. RESULTS: Here, we have analysed the global impact of the DNA relaxing agent novobiocin on gene expression in S. aureus. Using a novobiocin-resistant mutant, it became evident that the change in recA expression is due to gyrase inhibition. Microarray analysis and northern blot hybridisation revealed that the expression levels of a distinct set of genes were increased (e.g., recF-gyrB-gyrA, the rib operon and the ure operon) or decreased (e.g., arlRS, recA, lukA, hlgC and fnbA) by novobiocin. The two-component ArlRS system was previously found to decrease the level of supercoiling in S. aureus. Thus, downregulation of arlRS might partially compensate for the relaxing effect of novobiocin. Global analysis and gene mapping of supercoiling-sensitive genes did not provide any indication that they are clustered in the genome. Promoter fusion assays confirmed that the responsiveness of a given gene is intrinsic to the promoter region but independent of the chromosomal location. CONCLUSIONS: The results indicate that the molecular properties of a given promoter, rather than the chromosomal topology, dictate the responsiveness to changes in supercoiling in the pathogen Staphylococcus aureus. KW - aminocoumarins KW - novobiocin KW - microarray KW - Voronoi tree map KW - spacer KW - arlR KW - gyrase KW - supercoiling KW - staphylococcus aureus Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121609 SN - 1471-2164 VL - 15 IS - 291 ER - TY - THES A1 - Merget, Benjamin T1 - Computational methods for assessing drug-target residence times in bacterial enoyl-ACP reductases and predicting small-molecule permeability for the \(Mycobacterium\) \(tuberculosis\) cell wall T1 - Computermethoden zur Bestimmung von Protein-Ligand Verweilzeiten in bakteriellen Enoyl-ACP Reduktasen und Vorhersage der Permeabilitätswahrscheinlichkeit kleiner Moleküle gegenüber der \(Mycobacterium\) \(tuberculosis\) Zellwand N2 - \textbf{Molecular Determinants of Drug-Target Residence Times of Bacterial Enoyl-ACP Reductases.} Whereas optimization processes of early drug discovery campaigns are often affinity-driven, the drug-target residence time $t_R$ should also be considered due to an often strong correlation with \textit{in vivo} efficacy of compounds. However, rational optimization of $t_R$ is not straightforward and generally hampered by the lack of structural information about the transition states of ligand association and dissociation. The enoyl-ACP reductase FabI of the fatty acid synthesis (FAS) type II is an important drug-target in antibiotic research. InhA is the FabI enzyme of \textit{Mycobacterium tuberculosis}, which is known to be inhibited by various compound classes. Slow-onset inhibition of InhA is assumed to be associated with the ordering of the most flexible protein region, the substrate binding loop (SBL). Diphenylethers are one class of InhA inhibitors that can promote such SBL ordering, resulting in long drug-target residence times. Although these inhibitors are energetically and kinetically well characterized, it is still unclear how the structural features of a ligand affect $t_R$. Using classical molecular dynamics (MD) simulations, recurring conformational families of InhA protein-ligand complexes were detected and structural determinants of drug-target residence time of diphenyl\-ethers with different kinetic profiles were described. This information was used to deduce guidelines for efficacy improvement of InhA inhibitors, including 5'-substitution on the diphenylether B-ring. The validity of this suggestion was then analyzed by means of MD simulations. Moreover, Steered MD (SMD) simulations were employed to analyze ligand dissociation of diphenylethers from the FabI enzyme of \textit{Staphylococcus aureus}. This approach resulted in a very accurate and quantitative linear regression model of the experimental $ln(t_R)$ of these inhibitors as a function of the calculated maximum free energy change of induced ligand extraction. This model can be used to predict the residence times of new potential inhibitors from crystal structures or valid docking poses. Since correct structural characterization of the intermediate enzyme-inhibitor state (EI) and the final state (EI*) of two-step slow-onset inhibition is crucial for rational residence time optimization, the current view of the EI and EI* states of InhA was revisited by means of crystal structure analysis, MD and SMD simulations. Overall, the analyses affirmed that the EI* state is a conformation resembling the 2X23 crystal structure (with slow-onset inhibitor \textbf{PT70}), whereas a twist of residues Ile202 and Val203 with a further opened helix $\alpha 6$ corresponds to the EI state. Furthermore, MD simulations emphasized the influence of close contacts to symmetry mates in the SBL region on SBL stability, underlined by the observation that an MD simulation of \textbf{PT155} chain A with chain B' of a symmetry mate in close proximity of the SBL region showed significantly more stable loops, than a simulation of the tetrameric assembly. Closing Part I, SMD simulations were employed which allow the delimitation of slow-onset InhA inhibitors from rapid reversible ligands. \textbf{Prediction of \textit{Mycobacterium tuberculosis} Cell Wall Permeability.} The cell wall of \textit{M. tuberculosis} hampers antimycobacterial drug design due to its unique composition, providing intrinsic antibiotic resistance against lipophilic and hydrophilic compounds. To assess the druggability space of this pathogen, a large-scale data mining endeavor was conducted, based on multivariate statistical analysis of differences in the physico-chemical composition of a normally distributed drug-like chemical space and a database of antimycobacterial--and thus very likely permeable--compounds. The approach resulted in the logistic regression model MycPermCheck, which is able to predict the permeability probability of small organic molecules based on their physico-chemical properties. Evaluation of MycPermCheck suggests a high predictive power. The model was implemented as a freely accessible online service and as a local stand-alone command-line version. Methodologies and findings from both parts of this thesis were combined to conduct a virtual screening for antimycobacterial substances. MycPermCheck was employed to screen the chemical permeability space of \textit{M. tuberculosis} from the entire ZINC12 drug-like database. After subsequent filtering steps regarding ADMET properties, InhA was chosen as an exemplary target. Docking to InhA led to a principal hit compound, which was further optimized. The quality of the interaction of selected derivatives with InhA was subsequently evaluated using MD and SMD simulations in terms of protein and ligand stability, as well as maximum free energy change of induced ligand egress. The results of the presented computational experiments suggest that compounds with an indole-3-acethydrazide scaffold might constitute a novel class of InhA inhibitors, worthwhile of further investigation. N2 - \textbf{Molekulare Determinanten von Wirkstoff-Angriffsziel Verweilzeiten bakterieller Enoyl-ACP Reduktasen.} In frühen Phasen der Wirkstoffentwicklung sind Optimierungsprozesse häufig affini\-täts\-geleitet. Darüber hinaus sollte zusätzlich die Wirkstoff-Angriffsziel Verweilzeit $t_R$ berücksichtigt werden, da diese oft eine starke Korrelation zur \textit{in vivo} Wirksamkeit der Substanzen aufweist. Rationale Optimierung von $t_R$ ist jedoch auf Grund eines Mangels an struktureller Information über den Übergangszustand der Ligandbindung und Dissoziierung nicht einfach umsetzbar. Die Enoyl-ACP Reduktase FabI der Fettsäurebio\-synthese (FAS) Typ II ist ein wichtiger Angriffspunkt in der Antibiotikaforschung. InhA ist das FabI Enzym des Organismus \textit{Mycobacterium tuberculosis} und kann durch Substanzen diverser Klassen gehemmt werden. Es wird vermutet, dass Hemmung von InhA durch langsam-bindende (``slow-onset'') Inhibitoren mit der Ordnung der flexibelsten Region des Enzyms assoziiert ist, dem Substratbindungsloop (SBL). Diphenylether sind eine InhA Inhibitorenklasse, die eine solche SBL Ordnung fördern und dadurch lange Verweilzeiten im Angriffsziel aufweisen. Obwohl diese Inhibitoren energetisch und kinetisch gut charakterisiert sind, ist noch immer unklar, wie die strukturellen Eigenschaften eines Liganden $t_R$ beeinflussen. Durch die Verwendung klassischer Molekulardynamik (MD) Simulationen wurden wiederkehrende Konformationsfamilien von InhA Protein-Ligand Komplexen entdeckt und strukturelle Determinanten der Wirkstoff-Angriffsziel Verweilzeit von Diphenylethern mit verschiedenen kinetischen Profilen beschrieben. Anhand dieser Ergebnisse wurden Richtlinien zur Wirksamkeitsoptimierung von InhA Inhibitoren abgeleitet, einschließlich einer 5'-Substitution am Diphenylether B-Ring. Die Validität dieses Vorschlags wurde mittels MD Simulationen nachfolgend analysiert. Darüber hinaus wurden ``Steered MD'' (SMD) Simulationen als MD Technik für umfangreicheres Sampling verwendet um die Liganddissoziation von Diphenylethern aus dem FabI Enzym von \textit{Staphylococcus aureus} zu untersuchen. Dieser Ansatz resultierte in einem sehr akkuraten, quantitativen linearen Regressionsmodell der experimentellen Verweilzeit $ln(t_R)$ dieser Inhibitoren als Funktion der berechneten maximalen freien Energieänderung induzierter Ligandextraktion. Dieses Modell kann genutzt werden um die Verweilzeiten neuer potentieller Inhibitoren aus Kristallstrukturen oder validen Dockingposen vorherzusagen. Die korrekte strukturelle Charakterisierung des intermediären und des finalen Zustandes (EI und EI*-Zustand) eines Enzym-Inhibitor Komplexes bei einem zweistufigen Inhibitionsmechanismus durch langsam-bindende Hemmstoffe ist essentiell für rationale Verweilzeitoptimierung. Daher wurde die gegenwärtige Ansicht des EI und EI*-Zustandes von InhA mittels Kristallstrukturanalyse, MD und SMD Simulationen erneut aufgegriffen. Insgesamt bestätigten die Analysen, dass der EI*-Zustand einer Konformation ähnlich der 2X23 Kristallstruktur (mit langsam-bindenden Inhibitor \textbf{PT70}) gleicht, während eine Drehung der Reste Ile202 und Val203 mit einer weiter geöffneten Helix $\alpha 6$ dem EI-Zustand entspricht. Des Weiteren zeigten MD Simulationen den Einfluss naher Kristallkontakte zu Symmetrie-Nachbarn in der SBL Region auf die SBL Stabilität. Dies wird durch die Beobachtung hervorgehoben, dass die Ketten A und B' eines InhA-\textbf{PT155}-Komplexes und des angrenzenden Symmetrie-Nachbars, welche in engem Kontakt in der SBL Region stehen, signifikant stabilere SBLs aufweisen, als die Ketten A und B in einer Simulation des Tetramers. Zum Abschluss von Teil I wurden SMD Simulationen angewandt, auf deren Basis es möglich war, langsam-bindende InhA Inhibitoren von schnell-reversiblen (``rapid reversible'') Liganden zu unterscheiden. \textbf{Vorhersage von \textit{Mycobacterium tuberculosis} Zellwand Permeabilität.} Die Zellwand von \textit{M.~tuberculosis} erschwert die antimycobakterielle Wirkstofffindung auf Grund ihrer einzigartigen Zusammensetzung und bietet eine intrinsische Antibiotikaresistenz gegenüber lipophilen und hydrophilen Substanzen. Um den chemischen Raum wirkstoffähnlicher Moleküle gegen diesen Erreger (``Druggability Space'') einzugrenzen, wurde eine groß angelegte Dataminingstudie durchgeführt, welche auf multivariater statistischer Analyse der Unterschiede der physikochemischen Zusammensetzung eines normalverteilten wirkstoffähnlichen chemischen Raumes und einer Datenbank von antimycobakteriellen -- und somit höchstwahrscheinlich permeablen -- Substanzen beruht. Dieser Ansatz resultierte in dem logistischen Regressionsmodell MycPermCheck, welches in der Lage ist die Permeabilitätswahrscheinlichkeit kleiner organischer Moleküle anhand ihrer physikochemischen Eigenschaften vorherzusagen. Die Evaluation von MycPermCheck deutet auf eine große Vorhersagekraft hin. Das Modell wurde als frei zugänglicher online Service und als lokale Kommandozeilenversion implementiert. Methodiken und Ergebnisse aus beiden Teilen dieser Dissertation wurden kombiniert um ein virtuelles Screening nach antimycobakteriellen Substanzen durchzuführen. Myc\-PermCheck wurde verwendet um den chemischen Permeabilitätsraum von \textit{M.~tuberculosis} anhand der gesamten ZINC12 Datenbank wirkstoffähnlicher Moleküle abzuschätzen. Nach weiteren Filterschritten mit Bezug auf ADMET Eigenschaften, wurde InhA als exemplarisches Angriffsziel ausgewählt. Docking nach InhA führte schließlich zu einer Treffersubstanz, welche in darauffolgenden Schritten weiter optimiert wurde. Die Interaktionsqualität ausgewählter Derivate mit InhA wurde daraufhin mittels MD und SMD Simulationen in Bezug auf Protein und Ligand Stabilität, sowie auch der maximalen freien Energieänderung induzierter Ligandextraktion, untersucht. Die Ergebnisse der vorgestellten computerbasierten Experimente legen nahe, dass Substanzen mit einem Indol-3-Acethydrazid Gerüst eine neuartige Klasse von InhA Inhibitoren darstellen könnten. Weiterführende Untersuchungen könnten sich somit als lohnenswert erweisen. KW - Computational chemistry KW - Arzneimitteldesign KW - Molekulardynamik KW - Permeabilität KW - Tuberkelbakterium KW - Computational drug-design KW - steered molecular dynamics KW - molecular dynamics KW - residence time KW - mycobacterium tuberculosis KW - staphylococcus aureus KW - permeability KW - InhA KW - FabI KW - Enoyl-acyl-carrier-protein-Reductase KW - Drug design KW - Computational chemistry Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127386 ER - TY - JOUR A1 - Lioliou, Efthimia A1 - Sharma, Cynthia M. A1 - Caldelari, Isabelle A1 - Helfer, Anne-Catherine A1 - Fechter, Pierre A1 - Vandenesch, François A1 - Vogel, Jörg A1 - Romby, Pascale T1 - Global Regulatory Functions of the Staphylococcus aureus Endoribonuclease III in Gene Expression JF - PLoS Genetics N2 - RNA turnover plays an important role in both virulence and adaptation to stress in the Gram-positive human pathogen Staphylococcus aureus. However, the molecular players and mechanisms involved in these processes are poorly understood. Here, we explored the functions of S. aureus endoribonuclease III (RNase III), a member of the ubiquitous family of double-strand-specific endoribonucleases. To define genomic transcripts that are bound and processed by RNase III, we performed deep sequencing on cDNA libraries generated from RNAs that were co-immunoprecipitated with wild-type RNase III or two different cleavage-defective mutant variants in vivo. Several newly identified RNase III targets were validated by independent experimental methods. We identified various classes of structured RNAs as RNase III substrates and demonstrated that this enzyme is involved in the maturation of rRNAs and tRNAs, regulates the turnover of mRNAs and non-coding RNAs, and autoregulates its synthesis by cleaving within the coding region of its own mRNA. Moreover, we identified a positive effect of RNase III on protein synthesis based on novel mechanisms. RNase III–mediated cleavage in the 5′ untranslated region (5′UTR) enhanced the stability and translation of cspA mRNA, which encodes the major cold-shock protein. Furthermore, RNase III cleaved overlapping 5′UTRs of divergently transcribed genes to generate leaderless mRNAs, which constitutes a novel way to co-regulate neighboring genes. In agreement with recent findings, low abundance antisense RNAs covering 44% of the annotated genes were captured by co-immunoprecipitation with RNase III mutant proteins. Thus, in addition to gene regulation, RNase III is associated with RNA quality control of pervasive transcription. Overall, this study illustrates the complexity of post-transcriptional regulation mediated by RNase III. KW - staphylococcus aureus KW - ribonucleases KW - messenger RNA KW - RNA sequencing KW - antisense RNA KW - RNA structure KW - RNA synthesis KW - RNA denaturation Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127219 VL - 8 IS - 6 ER - TY - JOUR A1 - Fraunholz, Martin A1 - Sinha, Bhanu T1 - Intracellular staphylococcus aureus: Live-in and let die JF - Frontiers in Cellular and Infection Microbiology N2 - Staphylococcus aureus uses a plethora of virulence factors to accommodate a diversity of niches in its human host. Aside from the classical manifestations of S. aureus-induced diseases, the pathogen also invades and survives within mammalian host cells. The survival strategies of the pathogen are as diverse as strains or host cell types used. S. aureus is able to replicate in the phagosome or freely in the cytoplasm of its host cells. It escapes the phagosome of professional and non-professional phagocytes, subverts autophagy, induces cell death mechanisms such as apoptosis and pyronecrosis, and even can induce anti-apoptotic programs in phagocytes. The focus of this review is to present a guide to recent research outlining the variety of intracellular fates of S. aureus. KW - staphylococcus aureus KW - bacterial persistence KW - host cell death KW - autophagy KW - phagocytosis KW - phagosomalescape Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123374 VL - 2 IS - 43 ER - TY - JOUR A1 - Schoenfelder, Sonja M. K. A1 - Marincola, Gabriella A1 - Geiger, Tobias A1 - Goerke, Christiane A1 - Wolz, Christiane A1 - Ziebuhr, Wilma T1 - Methionine Biosynthesis in Staphylococcus aureus Is Tightly Controlled by a Hierarchical Network Involving an Initiator tRNA-Specific T-box Riboswitch JF - PLoS Pathogens N2 - Abstract In line with the key role of methionine in protein biosynthesis initiation and many cellular processes most microorganisms have evolved mechanisms to synthesize methionine de novo. Here we demonstrate that, in the bacterial pathogen Staphylococcus aureus, a rare combination of stringent response-controlled CodY activity, T-box riboswitch and mRNA decay mechanisms regulate the synthesis and stability of methionine biosynthesis metICFE-mdh mRNA. In contrast to other Bacillales which employ S-box riboswitches to control methionine biosynthesis, the S. aureus metICFE-mdh mRNA is preceded by a 5′-untranslated met leader RNA harboring a T-box riboswitch. Interestingly, this T-box riboswitch is revealed to specifically interact with uncharged initiator formylmethionyl-tRNA \((tRNA_i^{fMet})\)while binding of elongator \(tRNA^{Met}\) proved to be weak, suggesting a putative additional function of the system in translation initiation control. met leader RNA/metICFE-mdh operon expression is under the control of the repressor CodY which binds upstream of the met leader RNA promoter. As part of the metabolic emergency circuit of the stringent response, methionine depletion activates RelA-dependent (p)ppGpp alarmone synthesis, releasing CodY from its binding site and thereby activating the met leader promoter. Our data further suggest that subsequent steps in metICFE-mdh transcription are tightly controlled by the 5′ met leader-associated T-box riboswitch which mediates premature transcription termination when methionine is present. If methionine supply is limited, and hence \((tRNA_i^{fMet})\) becomes uncharged, full-length met leader/metICFE-mdh mRNA is transcribed which is rapidly degraded by nucleases involving RNase J2. Together, the data demonstrate that staphylococci have evolved special mechanisms to prevent the accumulation of excess methionine. We hypothesize that this strict control might reflect the limited metabolic capacities of staphylococci to reuse methionine as, other than Bacillus, staphylococci lack both the methionine salvage and polyamine synthesis pathways. Thus, methionine metabolism might represent a metabolic Achilles' heel making the pathway an interesting target for future anti-staphylococcal drug development. Author Summary Prokaryote metabolism is key for our understanding of bacterial virulence and pathogenesis and it is also an area with huge opportunity to identify novel targets for antibiotic drugs. Here, we have addressed the so far poorly characterized regulation of methionine biosynthesis in S. aureus. We demonstrate that methionine biosynthesis control in staphylococci significantly differs from that predicted for other Bacillales. Notably, involvement of a T-box instead of an S-box riboswitch separates staphylococci from other bacteria in the order. We provide, for the first time, direct experimental proof for an interaction of a methionyl-tRNA-specific T-box with its cognate tRNA, and the identification of initiator \((tRNA_i^{fMet})\) as the specific binding partner is an unexpected finding whose exact function in Staphylococcus metabolism remains to be established. The data further suggest that in staphylococci a range of regulatory elements are integrated to form a hierarchical network that elegantly limits costly (excess) methionine biosynthesis and, at the same time, reliably ensures production of the amino acid in a highly selective manner. Our findings open a perspective to exploit methionine biosynthesis and especially its T-box-mediated control as putative target(s) for the development of future anti-staphylococcal therapeutics. KW - ribonucleases KW - transfer RNA KW - staphylococcus aureus KW - staphylococcus KW - biosynthesis KW - methionine KW - RNA synthesis KW - DNA transcription Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130365 VL - 9 IS - 9 ER - TY - JOUR A1 - Zhang, Nan A1 - Van Crombruggen, Koen A1 - Holtappels, Gabriele A1 - Lan, Feng A1 - Katotomichelakis, Michail A1 - Zhang, Luo A1 - Högger, Petra A1 - Bachert, Claus T1 - Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo JF - PLOS ONE N2 - Background: Topical glucocorticosteroids are the first line therapy for airway inflammation. Modern compounds with higher efficacy have been developed, but head-to-head comparison studies are sparse. Objective: To compare the activity of two intranasal glucocorticoids, fluticasone furoate (FF) and mometasone furoate (MF) with respect to the inhibition of T helper (Th)1, Th2 and Th17 cytokine release in airway mucosa. Methods: We used an ex-vivo human nasal mucosal tissue model and employed pre-and post-Staphylococcus aureus enterotoxin B (SEB)-challenge incubations with various time intervals and drug concentrations to mimic typical clinical situations of preventive or therapeutic use. Results: At a fixed concentration of 10(-10) M, FF had significantly higher suppressive effects on interferon (IFN)-gamma,interleukin (IL)-2 and IL-17 release, but not IL-5 or tumor necrosis factor (TNF)-alpha, vs. MF. While the maximal suppressive activity was maintained when FF was added before or after tissue stimulation, the cytokine suppression capacity of MF appeared to be compromised when SEB-induced cell activation preceded the addition of the drug. In a pre-challenge incubation setting with removal of excess drug concentrations, MF approached inhibition of IL-5 and TNF-alpha after 6 and 24 hours while FF maximally blocked the release of these cytokines right after pre-incubation. Furthermore, FF suppressed a wider range of T helper cytokines compared to MF. Conclusion: The study demonstrates the potential of our human mucosal model and shows marked differences in the ability to suppress the release of various cytokines in pre-and post-challenge settings between FF and MF mimicking typical clinical situations of preventive or therapeutic use. KW - allergic rhinitis KW - human receptor kinetics KW - staphylococcus aureus KW - intranasal corticosteroids KW - cells KW - propionate KW - secretion KW - affinity KW - therapy KW - spray Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116779 VL - 9 IS - 4 ER -